Cargando…

Calpain-2 expression is associated with response to platinum based chemotherapy, progression-free and overall survival in ovarian cancer

Ovarian cancer is routinely treated with surgery and platinum-based chemotherapy. Resistance is a major obstacle in the efficacy of this chemotherapy regimen and the ability to identify those patients at risk of developing resistance is of considerable clinical importance. The expression of calpain-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Storr, Sarah J, Safuan, Sabreena, Woolston, Caroline M, Abdel-Fatah, Tarek, Deen, Suha, Chan, Stephen Y, Martin, Stewart G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2012
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472029/ https://www.ncbi.nlm.nih.gov/pubmed/22435971 http://dx.doi.org/10.1111/j.1582-4934.2012.01559.x

Ejemplares similares

Calpain system protein expression and activity in ovarian cancer
por: Zhang, Siwei, et al.
Publicado: (2018)

Calpain system protein expression in basal-like and triple-negative invasive breast cancer
por: Storr, S. J., et al.
Publicado: (2012)

Expression of Syk and MAP4 proteins in ovarian cancer
por: Zhang, Siwei, et al.
Publicado: (2019)

Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab
por: Sostelly, Alexandre, et al.
Publicado: (2019)

Macrophage-derived interleukin-1beta promotes human breast cancer cell migration and lymphatic adhesion in vitro
por: Storr, Sarah J., et al.
Publicado: (2017)

High BMP7 expression is associated with poor prognosis in ovarian cancer
por: Vasan, Richa, et al.
Publicado: (2023)

Sri Petaling COVID-19 cluster in Malaysia: challenges and the mitigation strategies
por: Edinur, Hisham Atan, et al.
Publicado: (2020)

The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy
por: Storr, Sarah J., et al.
Publicado: (2016)

Dopamine and cAMP‐regulated phosphoprotein 32kDa (DARPP‐32), protein phosphatase‐1 and cyclin‐dependent kinase 5 expression in ovarian cancer
por: Martin, Stewart G., et al.
Publicado: (2020)

A panel of three oxidative stress-related genes predicts overall survival in ovarian cancer patients received platinum-based chemotherapy
por: Zhang, Jin, et al.
Publicado: (2018)

Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer
por: Paik, E Sun, et al.
Publicado: (2017)

Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy
por: Shehata, M, et al.
Publicado: (2009)

Peritumoral lymphatic vessel density and invasion detected with immunohistochemical marker D240 is strongly associated with distant metastasis in breast carcinoma
por: Norhisham, Nur Fatiha, et al.
Publicado: (2017)

Potential Effect of Polyphenolic-Rich Fractions of Corn Silk on Protecting Endothelial Cells against High Glucose Damage Using In Vitro and In Vivo Approaches
por: Hamzah, Nurraihana, et al.
Publicado: (2021)

Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers
por: Ali, Reem, et al.
Publicado: (2021)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
por: Grande, Enrique, et al.
Publicado: (2023)

Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival
por: Jernigan, Amelia M., et al.
Publicado: (2013)

The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer
por: Woolston, Caroline M, et al.
Publicado: (2012)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: A systematic review and MOOSE-compliant meta-analysis
por: Zhang, Zhuo, et al.
Publicado: (2018)

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial
por: Ledermann, J.A., et al.
Publicado: (2021)

The Immune Subtype Contributes to Distinct Overall Survival for Ovarian Cancer Patients With Platinum-Based Adjuvant Therapy
por: Li, Yueyi, et al.
Publicado: (2022)

Low calpain-9 is associated with adverse disease-specific survival following endocrine therapy in breast cancer
por: Davis, Jillian, et al.
Publicado: (2014)

Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla
por: Storr, Sarah J, et al.
Publicado: (2012)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

Calpains in cyanobacteria and the origin of calpains
por: Vešelényiová, Dominika, et al.
Publicado: (2022)

CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients
por: Heinze, Karolin, et al.
Publicado: (2021)

Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers
por: Ali, Reem, et al.
Publicado: (2021)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]
Publicado: (2014)

Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer
por: Yang, Ling, et al.
Publicado: (2022)

Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
por: Coffman, Lan G., et al.
Publicado: (2022)

Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer
por: Nara, Katsuhiko, et al.
Publicado: (2023)

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
por: Kaye, S. B., et al.
Publicado: (2011)

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
por: Friedlander, Michael, et al.
Publicado: (2018)

Data Mining of Gene Arrays for Biomarkers of Survival in Ovarian Cancer
por: Coveney, Clare, et al.
Publicado: (2015)

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy
por: Glaysher, S, et al.
Publicado: (2010)

The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer
por: Zhang, Jian-Wei, et al.
Publicado: (2014)

Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
por: Lee, C K, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_36d6cnb8u62relak4hojrgcrg9